AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4
Authors: Soni, R O'Reilly, T Furet, P Muller, L Stephan, C Zumstein-Mecker, S Fretz, H Fabbro, D Chaudhuri, B
Citation: R. Soni et al., Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4, J NAT CANC, 93(6), 2001, pp. 436
Convergent synthesis of potent peptide inhibitors of the Grb2-SH2 domain by palladium catalyzed coupling of a terminal alkyne
Authors: Schoepfer, J Gay, B End, N Muller, E Scheffel, G Caravatti, G Furet, P
Citation: J. Schoepfer et al., Convergent synthesis of potent peptide inhibitors of the Grb2-SH2 domain by palladium catalyzed coupling of a terminal alkyne, BIOORG MED, 11(9), 2001, pp. 1201-1203
Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction
Authors: Garcia-Echeverria, C Furet, P Chene, P
Citation: C. Garcia-echeverria et al., Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction, BIOORG MED, 11(16), 2001, pp. 2161-2164
A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome
Authors: Garcia-Echevarria, C Imbach, P France, D Furst, P Lang, M Noorani, M Scholz, D Zimmermann, J Furet, P
Citation: C. Garcia-echevarria et al., A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome, BIOORG MED, 11(10), 2001, pp. 1317-1319
Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design
Authors: Furet, P Imbach, P Furst, P Lang, M Noorani, M Zimmermann, J Garcia-Echeverria, C
Citation: P. Furet et al., Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design, BIOORG MED, 11(10), 2001, pp. 1321-1324
Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching
Authors: Furet, P Meyer, T Mittl, P Fretz, H
Citation: P. Furet et al., Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching, J COMPUT A, 15(5), 2001, pp. 489-495
Tyrosine kinase inhibitors: From rational design to clinical trials
Authors: Traxler, P Bold, G Buchdunger, E Caravatti, G Furet, P Manley, P O'Reilly, T Wood, J Zimmermann, J
Citation: P. Traxler et al., Tyrosine kinase inhibitors: From rational design to clinical trials, MED RES REV, 21(6), 2001, pp. 499-512
New synthesis of oxcarbazepine via remote metalation of protected N-o-tolyl-anthranilamide derivatives
Authors: Lohse, O Beutler, U Funfschilling, P Furet, P France, J Kaufmann, D Penn, G Zaugg, W
Citation: O. Lohse et al., New synthesis of oxcarbazepine via remote metalation of protected N-o-tolyl-anthranilamide derivatives, TETRAHEDR L, 42(3), 2001, pp. 385-389
Total synthesis and biological evaluation of the nakijiquinones
Authors: Stahl, P Kissau, L Mazitschek, R Huwe, A Furet, P Giannis, A Waldmann, H
Citation: P. Stahl et al., Total synthesis and biological evaluation of the nakijiquinones, J AM CHEM S, 123(47), 2001, pp. 11586-11593
Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways
Authors: Fretz, H Furet, P Garcia-Echeverria, C Rahuel, J Schoepfer, J
Citation: H. Fretz et al., Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways, CUR PHARM D, 6(18), 2000, pp. 1777-1796
2,6,9-trisubstituted purines: Optimization towards highly potent and selective CDK1 inhibitors (vol 9, pg 91, 1999)
Authors: Imbach, P Capraro, HG Furet, P Mett, H Meyer, T Zimmermann, J
Citation: P. Imbach et al., 2,6,9-trisubstituted purines: Optimization towards highly potent and selective CDK1 inhibitors (vol 9, pg 91, 1999), BIOORG MED, 10(9), 2000, pp. 1001-1001
Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1
Authors: Furet, P Caravatti, G Denholm, AA Faessler, A Fretz, H Garcia-Echeverria, C Gay, B Irving, E Press, NJ Rahuel, J Schoepfer, J Walker, CV
Citation: P. Furet et al., Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1, BIOORG MED, 10(20), 2000, pp. 2337-2341
Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2
Authors: Walker, CV Caravatti, G Denholm, AA Egerton, J Faessler, A Furet, P Garcia-Echeverria, C Gay, B Irving, E Jones, K Lambert, A Press, NJ Woods, J
Citation: Cv. Walker et al., Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2, BIOORG MED, 10(20), 2000, pp. 2343-2346
Structure-based design of potent CDK1 inhibitors derived from olomoucine
Authors: Furet, P Zimmermann, J Capraro, HG Meyer, T Imbach, P
Citation: P. Furet et al., Structure-based design of potent CDK1 inhibitors derived from olomoucine, J COMPUT A, 14(5), 2000, pp. 403-409
A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines
Authors: Chene, P Fuchs, J Bohn, J Garcia-Echeverria, C Furet, P Fabbro, D
Citation: P. Chene et al., A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines, J MOL BIOL, 299(1), 2000, pp. 245-253
Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53
Authors: Garcia-Echeverria, C Chene, P Blommers, MJJ Furet, P
Citation: C. Garcia-echeverria et al., Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53, J MED CHEM, 43(17), 2000, pp. 3205-3208
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis (vol 43, pg 2316, 2000)
Authors: Bold, G Altmann, KH Frei, J Lang, M Manley, PW Traxler, P Wietfeld, B Bruggen, J Buchdunger, E Cozens, R Ferrari, S Furet, P Hofmann, F Martiny-Baron, G Mestan, J Rosel, J Sills, M Stover, D Acemoglu, F Boss, E Emmenegger, R Lasser, L Masso, E Roth, R Schlachter, C Vetterli, W Wyss, D Wood, JM
Citation: G. Bold et al., New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis (vol 43, pg 2316, 2000), J MED CHEM, 43(16), 2000, pp. 3200-3200
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
Authors: Bold, G Altmann, KH Frei, J Lang, M Manley, PW Traxler, P Wietfeld, B Bruggen, J Buchdunger, E Cozens, R Ferrari, S Furet, P Hofmann, F Martiny-Baron, G Mestan, J Rosel, J Sills, M Stover, D Acemoglu, F Boss, E Emmenegger, R Lasser, L Masso, E Roth, R Schlachter, C Vetterli, W Wyss, D Wood, JM
Citation: G. Bold et al., New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis, J MED CHEM, 43(12), 2000, pp. 2310-2323
Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product
Authors: Soni, R Muller, L Furet, P Schoepfer, J Stephan, C Zumstein-Mecker, S Fretz, H Chaudhuri, B
Citation: R. Soni et al., Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product, BIOC BIOP R, 275(3), 2000, pp. 877-884
Mapping the X+1 binding site of the Grb2-SH2 domain with alpha,alpha-disubstituted cyclic alpha-amino acids
Authors: Garcia-Echeverria, C Gay, B Rahuel, J Furet, P
Citation: C. Garcia-echeverria et al., Mapping the X+1 binding site of the Grb2-SH2 domain with alpha,alpha-disubstituted cyclic alpha-amino acids, BIOORG MED, 9(20), 1999, pp. 2915-2920
Highly potent inhibitors of the Grb2-SH2 domain
Authors: Schoepfer, J Fretz, H Gay, B Furet, P Garcia-Echeverria, C End, N Caravatti, G
Citation: J. Schoepfer et al., Highly potent inhibitors of the Grb2-SH2 domain, BIOORG MED, 9(2), 1999, pp. 221-226
Structure-based design of a non-peptidic antagonist of the SH2 domain of Grb2
Authors: Caravatti, G Rahuel, J Gay, B Furet, P
Citation: G. Caravatti et al., Structure-based design of a non-peptidic antagonist of the SH2 domain of Grb2, BIOORG MED, 9(14), 1999, pp. 1973-1978
2,6,9-trisubstituted purines: Optimization towards highly potent and selective CDK1 inhibitors
Authors: Imbach, P Capraro, HG Furet, P Mett, H Meyer, T Zimmermann, J
Citation: P. Imbach et al., 2,6,9-trisubstituted purines: Optimization towards highly potent and selective CDK1 inhibitors, BIOORG MED, 9(1), 1999, pp. 91-96
Strategies toward the design of novel and selective protein tyrosine kinase inhibitors
Authors: Traxler, P Furet, P
Citation: P. Traxler et P. Furet, Strategies toward the design of novel and selective protein tyrosine kinase inhibitors, PHARM THERA, 82(2-3), 1999, pp. 195-206
Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-phenyl-4(1H)-quinolones
Authors: Traxler, P Green, J Mett, H Sequin, U Furet, P
Citation: P. Traxler et al., Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-phenyl-4(1H)-quinolones, J MED CHEM, 42(6), 1999, pp. 1018-1026
Risultati: 1-25 | 26-28